What is the 13F Pro Quality Score for RDY?

13F Pro ranks DR REDDYS LABORATORIES LTD (RDY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RDY's current score at https://13fpro.ai/company/RDY (free sign-up required for the full ranking).

Where does 13F Pro source RDY data?

All DR REDDYS LABORATORIES LTD fundamentals and ownership data come directly from SEC EDGAR. DR REDDYS LABORATORIES LTD files with the SEC under CIK 1135951. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RDY in?

DR REDDYS LABORATORIES LTD (RDY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RDY research updated on 13F Pro?

RDY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

DR REDDYS LABORATORIES LTD(RDY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1135951 RDY stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

47.6/100

Rank #1,768 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why RDY Scores 48/100

exact factor attribution · 2026-09-11

RDY's composite is driven by profitability and capital efficiency, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+3.9 pts

76th pct

Capital efficiency

+3.8 pts

88th pct

Shareholder dilution

+2.1 pts

93th pct

Institutional flow

+0.8 pts

67th pct

Earnings growth

-1.0 pts

30th pct

Earnings quality

-2.0 pts

30th pct

Free cash flow

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

RDY Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for DR REDDYS LABORATORIES LTD (RDY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RDY at 47.6/100 on a 32-signal composite quality model, placing it at rank #1,768 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), DR REDDYS LABORATORIES LTD reports quarterly revenue of $3.8B, net income of $671.0M. Top institutional holders of RDY by reported 13-F value include Robeco Institutional Asset Management B.V., MORGAN STANLEY, BlackRock, based on the most recent SEC filings. RDY trades on the NYSE exchange and files with the SEC under CIK 1135951. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RDY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DR REDDYS LABORATORIES LTD directly from SEC EDGAR. DR REDDYS LABORATORIES LTD's 13F Pro composite quality score has ranged between 46 and 50 since 2026, currently 47.6 — a stable long-term trajectory across 47 quarterly and live scoring snapshots.

Revenue

FY 2025

$3.8B

Net Income

FY 2025

$671.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+16.6% YoY

$325.54BFY 2025

FY22 $214.39BFY23 $245.88BFY24 $279.16BFY25 $325.54B

Total Assets

+27.2% YoY

$492.99BFY 2025

FY22 $292.83BFY23 $321.85BFY24 $387.52BFY25 $492.99B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$325.54B +16.6%	$279.16B +13.5%	$245.88B +14.7%	$214.39B +13.0%	$189.72B +8.7%	$174.60B
Total Assets	$492.99B +27.2%	$387.52B +20.4%	$321.85B +9.9%	$292.83B +10.3%	$265.49B +14.3%	$232.24B

Get alerted when RDY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DR REDDYS LABORATORIES LTD including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RDY

Robeco Institutional Asset Management B.V.
$261.1M18,021,100 sh
MORGAN STANLEY
$158.5M10,936,320 sh
BlackRock, Inc.
$153.4M10,585,742 sh
ROYAL BANK OF CANADA
$133.5M9,213,269 sh
Aikya Investment Management Ltd
$123.1M8,493,852 sh
RENAISSANCE TECHNOLOGIES LLC
$106.5M7,347,028 sh
DIMENSIONAL FUND ADVISORS LP
$77.0M5,312,065 sh
JPMORGAN CHASE & CO
$60.5M4,069,357 sh
STATE STREET CORP
$59.8M4,124,686 sh
ALLIANCEBERNSTEIN L.P.
$51.7M3,730,713 sh

Fund	Value	Shares
Robeco Institutional Asset Management B.V.	$261.1M	18,021,100
MORGAN STANLEY	$158.5M	10,936,320
BlackRock, Inc.	$153.4M	10,585,742
ROYAL BANK OF CANADA	$133.5M	9,213,269
Aikya Investment Management Ltd	$123.1M	8,493,852
RENAISSANCE TECHNOLOGIES LLC	$106.5M	7,347,028
DIMENSIONAL FUND ADVISORS LP	$77.0M	5,312,065
JPMORGAN CHASE & CO	$60.5M	4,069,357
STATE STREET CORP	$59.8M	4,124,686
ALLIANCEBERNSTEIN L.P.	$51.7M	3,730,713

Companies Similar to RDY

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CHT

CHUNGHWA TELECOM CO LTD

AI score

Shared smart-money ownership · 26 shared holders

Robeco Institutional Asset Management B.V.B. Metzler seel. Sohn & Co. AG Laird Norton Wetherby Wealth Management, LLC

AZN

ASTRAZENECA PLC

AI score

Similar quality profile · 4 shared holders

Migdal Insurance & Financial Holdings Ltd.LGT Group Foundation Crestwood Advisors Group, LLC

PHG

KONINKLIJKE PHILIPS NV

AI score

Similar quality profile · 13 shared holders

Laird Norton Wetherby Wealth Management, LLC GREENLEAF TRUST XY Capital Ltd

HCM

HUTCHMED (China) Ltd

AI score

Similar quality profile · 1 shared holders

XY Capital Ltd

UMC

UNITED MICROELECTRONICS CORP

AI score

Similar quality profile · 25 shared holders

B. Metzler seel. Sohn & Co. AG Robeco Institutional Asset Management B.V.Laird Norton Wetherby Wealth Management, LLC

WIT

WIPRO LTD

AI score

Shared smart-money ownership · 29 shared holders

Robeco Institutional Asset Management B.V.B. Metzler seel. Sohn & Co. AG Laird Norton Wetherby Wealth Management, LLC

INFY

Infosys Ltd

AI score

Shared smart-money ownership · 20 shared holders

Robeco Institutional Asset Management B.V.B. Metzler seel. Sohn & Co. AG Aikya Investment Management Ltd

GSK

GSK plc

AI score

Similar quality profile · 2 shared holders

LOGAN CAPITAL MANAGEMENT INC Grantham, Mayo, Van Otterloo & Co. LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RDY on your watchlist

Track score changes the day DR REDDYS LABORATORIES LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RDY a good stock to buy?

13F Pro's AI-powered analysis of DR REDDYS LABORATORIES LTD (RDY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RDY are available on the RDY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RDY is classified as a mid company.

Which hedge funds own RDY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RDY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DR REDDYS LABORATORIES LTD's investment landscape.